#1 Clinical Trials Search in Europe

Ngm707

NGM707 is an innovative drug currently being studied in clinical trials for the treatment of various advanced or metastatic solid tumor malignancies. This article explores the ongoing research on NGM707, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®), to evaluate its safety, efficacy, and potential benefits for patients with different types of cancer.

Table of Contents

What is NGM707?

NGM707 is a new drug currently being studied for its potential to treat various types of advanced or metastatic solid tumors[1]. It is undergoing clinical trials to evaluate its effectiveness and safety when used alone or in combination with another drug called pembrolizumab (also known by its brand name KEYTRUDA®).

What conditions does NGM707 treat?

The clinical trial is investigating NGM707’s effectiveness in treating several types of advanced or metastatic solid tumors, including[1]:

  • Non-Small Cell Lung Cancer (NSCLC): A common type of lung cancer that affects the cells lining the airways
  • Renal Cell Carcinoma: A type of kidney cancer
  • Squamous Cell Carcinoma of Head and Neck (SCCHN): Cancer that begins in the flat cells lining the mouth, nose, throat, or voice box
  • Pancreatic Ductal Adenocarcinoma: The most common type of pancreatic cancer
  • Cholangiocarcinoma: Cancer that forms in the bile ducts
  • Colorectal Cancer: Cancer that starts in the colon or rectum
  • Esophageal Cancer: Cancer of the tube that connects the throat to the stomach
  • Ovarian Cancer: Cancer that begins in the ovaries
  • Mesothelioma: Cancer that affects the lining of the lungs, chest wall, or abdomen
  • Glioblastoma: An aggressive type of brain cancer
  • Melanoma: A type of skin cancer
  • Gastric Cancer: Cancer that begins in the stomach
  • Breast Cancer
  • Cervical Cancer and Endocervical Cancer: Cancers affecting the cervix

How is NGM707 administered?

NGM707 is given to patients through an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein[1]. The drug is administered every 3 weeks in what’s called a 21-day cycle. During the clinical trial, researchers are testing multiple dose levels to determine the most effective and safe dose for patients.

NGM707 in combination with Pembrolizumab

One of the key aspects of this clinical trial is studying how NGM707 works when combined with another drug called pembrolizumab (KEYTRUDA®)[1]. Pembrolizumab is an immunotherapy drug that helps the body’s immune system detect and fight cancer cells. In the combination therapy, both NGM707 and pembrolizumab are given intravenously every 3 weeks in a 21-day cycle.

Current clinical trial of NGM707

The ongoing clinical trial for NGM707 is a Phase 1/2 study, which means it’s in the early stages of testing in humans[1]. The trial is divided into several parts:

  1. Dose Escalation: This part aims to find the right dose of NGM707 when used alone.
  2. Combination Dose Finding: This part tests different doses of NGM707 when used with pembrolizumab.
  3. Dose Expansion: This part further tests the chosen doses in specific cancer types, including:
    • Squamous Non-Small Cell Lung Cancer
    • Non-Squamous Non-Small Cell Lung Cancer
    • Squamous Cell Carcinoma of Head and Neck
    • Ovarian Cancer

Safety and efficacy measures

The clinical trial is collecting important information about NGM707’s safety and how well it works[1]. Some of the key things they’re looking at include:

  • Safety: They’re monitoring for any side effects or adverse events that patients experience during treatment.
  • Effectiveness: They’re measuring how well the drug works by looking at things like:
    • How many patients have their tumors shrink or disappear (called “objective response rate”)
    • How long the drug keeps working (called “duration of response”)
    • How long patients live without their cancer getting worse (called “progression-free survival”)
    • How long patients live overall (called “overall survival”)
  • Drug behavior in the body: They’re studying how the drug moves through the body, how long it stays in the system, and whether patients develop antibodies against the drug.

It’s important to note that as NGM707 is still in clinical trials, it’s not yet approved for general use. The results of this study will help determine if NGM707 could become a new treatment option for patients with advanced solid tumors in the future.

Aspect Details
Drug Name NGM707
Study Type Phase 1/2 Dose Escalation/Expansion Study
Administration Intravenous (IV) every 3 weeks in a 21-day cycle
Treatment Arms Monotherapy and Combination with pembrolizumab (KEYTRUDA®)
Cancer Types Various advanced or metastatic solid tumor malignancies
Primary Outcomes Safety (adverse events, dose-limiting toxicities), Efficacy (objective response rate, duration of response, progression-free survival, overall survival)
Secondary Outcomes Pharmacokinetics (plasma concentration, half-life), Anti-drug antibodies
Study Duration Up to approximately 48 months for some outcomes

FAQ

  • What is NGM707 and what types of cancer is it being studied for? NGM707 is a new drug being investigated for the treatment of advanced or metastatic solid tumor malignancies. It is being studied for various types of cancer, including non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal cancer, esophageal cancer, and ovarian cancer, among others.
  • How is NGM707 administered in the clinical trials? In the clinical trials, NGM707 is given intravenously (IV) every 3 weeks in a 21-day cycle. The study is evaluating multiple dose levels to determine the most effective and safe dosage.
  • Is NGM707 being studied alone or in combination with other drugs? NGM707 is being studied both as a monotherapy (alone) and in combination with pembrolizumab (KEYTRUDA®), another cancer drug. The combination therapy is being investigated to see if it provides better results than either drug alone.
  • What are the main goals of the NGM707 clinical trials? The main goals of the NGM707 clinical trials include assessing the safety of the drug by monitoring adverse events and dose-limiting toxicities, evaluating its effectiveness in treating various types of cancer, and studying how the drug behaves in the body (pharmacokinetics).
  • How long do the NGM707 clinical trials last? The duration of the NGM707 clinical trials varies depending on the specific outcomes being measured. Some assessments are made within the first 28 days, while others continue for approximately 24 months. For overall survival in combination therapy groups, the follow-up can last up to approximately 48 months.

Ongoing Clinical Trials on Ngm707

  • Study of NGM707 and Pembrolizumab for Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Monotherapy: Treatment using a single drug or method, in this case, using NGM707 alone to treat cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Solid Tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Intravenous (IV): A method of administering medications or fluids directly into a vein.
  • Dose-limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Objective Response: A measurable response to treatment, typically referring to a reduction in tumor size.
  • Progression-free Survival: The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival: The length of time from the start of treatment until death from any cause.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Anti-drug Antibodies (ADA): Antibodies produced by the body's immune system in response to a drug, which can potentially reduce the drug's effectiveness.

References